CAR 细胞疗法在急性髓系白血病中的进展与挑战
陈嘉莹 ,李敏 ,田晨 *
作者信息
- 天津医科大学肿瘤医院血液科,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,天津 300060
*通信作者
摘要
急性髓系白血病(AML)是一种高度异质性的血液系统恶性肿瘤,传统治疗手段疗效有限,复发、耐药问题突出。 目前嵌合抗原受体(CAR)细胞疗法已成为免疫治疗领域的新兴热点,其中 CAR-T 细胞疗法在 AML 早期研究中已展现出巨大治疗潜力,CD33、CD123、C-型凝集素样分子1(CLL-)等多种靶点均已被广泛研究,同时CAR-自然杀伤(NK)、CAR-自然杀伤性 T(NKT)细胞等新型 CAR细胞疗法也快速发展。 但 CAR 细胞疗法在 AML 中的应用仍面临理想靶抗原缺乏、安全性问题突出、疗效有待提升及治疗后疾病复发等诸多挑战。本文就 CAR 细胞疗法在 AML 领域的研究进展、核心挑战及改进策略进行系统综述,为其基础研究和临床转化提供参考。
Advances and challenges in CAR cell therapy for acute myeloid leukemia
Jiaying CHEN , Min LI , Chen TIAN *
Author Information
- Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer,Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
*Corresponding author
Abstract
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy for which conventional treatments offer limited efficacy, with prominent recurrence and drug resistance remaining major clinical problems. Currently, chimeric antigen receptor ( CAR) cell therapy has emerged as a new hotspot in the field of immunotherapy. CAR-T cell therapy has shown great therapeutic potential in early-stage studies of AML. Numerous studies have focused on several targets such as CD33, CD123, and C - type lectin-like molecule -1 ( CLL-1), alongside the rapid development of novel CAR cell therapies, including CAR-natural killer (NK) and CAR-natural killer T (NKT) cells. However, the application of CAR cell therapy in AML still faces many challenges, including the lack of ideal target antigens, significant safety issues, limited therapeutic efficacy, and disease recurrence after treatment. This article systematically reviews the research progress, challenges, and optimization strategies of CAR cell therapies in the field of AML, so as to provide a reference for its basic research and clinical translation.
